Doç. Dr. İbrahim KARADAĞ

1. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

Telli T. A., Tatlı A. M., ALAN Ö., Keskin G. Y., KARADURMUŞ N., KARAKAYA S., et al.

Clinical Lung Cancer , cilt.26, sa.8, 2025 (SCI-Expanded, Scopus)

2. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., KARAKAYA S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

3. Adjuvant Temozolomide Therapy Tolerance in Geriatric Glioblastoma Multiforme Patients

İnci B. K., KARADAĞ İ., İşbilir G. D., TOMAR V. B., GÜRLER F., KUBİLAY TOLUNAY P., et al.

European Journal of Geriatrics and Gerontology , cilt.6, sa.3, ss.165-170, 2024 (ESCI, Scopus, TRDizin)

4. Clinicopathological features of non-carcinoid malignant epithelial appendix tumors and risk factors for recurrence, single-center experience

ATEŞ Ö., AKSEL B., KARADAĞ İ., KARAKAYA S., Sunar V., Oksuzoglu O. B.

Indian Journal of Cancer , cilt.61, sa.2, ss.305-311, 2024 (SCI-Expanded, Scopus)

5. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy

Ilhan Y., Ucar G., Baser M. N., Guzel H. G., Efil S. C., Demir B., et al.

Expert Opinion on Pharmacotherapy , cilt.25, sa.11, ss.1555-1563, 2024 (SCI-Expanded, Scopus)

6. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.

BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus)

7. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

BİLİCİ A., Olmez O. F., Kaplan M. A., Oksuzoglu B., Sezer A., KARADURMUŞ N., et al.

Acta Oncologica , cilt.62, sa.4, ss.381-390, 2023 (SCI-Expanded, Scopus)

8. The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer

KARADAĞ İ., KARAKAYA S., AKKAN T., Demir B., Alkurt E. G., DOĞAN M.

Cancer Management and Research , cilt.15, ss.311-317, 2023 (SCI-Expanded, Scopus)

9. Non-Invasive Liver Fibrosis Scores can Predict Hepatic Metastasis in Colorectal Cancers

KARAKAYA S., KARADAĞ İ., ATEŞ Ö.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.32, sa.2, ss.102-108, 2022 (SCI-Expanded, Scopus, TRDizin)

10. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer

KARADAĞ İ., KARAKAYA S., YILMAZ M., ÇAKMAK ÖKSÜZOĞLU Ö. B.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.20, ss.7679-7686, 2022 (SCI-Expanded, Scopus)

11. CA-125/CEA RATIO AS A PROGNOSTIC FACTOR IN TYPE II ENDOMETRIAL CANCER: A SINGLE INSTITUTE EXPERIENCE

KARADAĞ İ., KARAKAYA S., Ateş O., Çakmak Öksüzoğlu O. B.

World Cancer Research Journal , cilt.9, 2022 (Scopus)

12. Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study

Gurbuz M., Dogan I., Akkus E., KARADAĞ İ., KARAKAYA S., Erol C., et al.

Journal of Oncological Science , cilt.8, sa.1, ss.14-19, 2022 (Scopus, TRDizin)

13. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Karacin C., EREN T., Zeynelgil E., İMAMOĞLU G. İ., ALTINBAŞ M., KARADAĞ İ., et al.

Future Oncology , cilt.17, sa.33, ss.4447-4456, 2021 (SCI-Expanded, Scopus)

14. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data

ATEŞ Ö., Oksuzoglu O. B., AKTAŞ B. Y., KARADAĞ İ., Esen S., KARAKAYA S., et al.

Journal of B.U.ON. , cilt.26, sa.4, ss.1398-1404, 2021 (SCI-Expanded, Scopus)

15. Evaluation of Cancer Patients with Older Adult for Awareness and Hospital Arrival Process of COVID-19 Pandemic During: A Cross-Sectional Study

Sipahi Karslı Z., KURT B., KARADAĞ İ., Çakmak Öksüzoğlu B.

Gerontology and Geriatric Medicine , cilt.7, 2021 (ESCI, Scopus)

16. The easy way of evaluating exocrine pancreatic insufficiency in type 2 diabetes: Listen to the patients’ complaints and look in their eyes!

Aksoz Z., AKKAN T., BEYAN E., Dagdeviren M., Mete Yildirim A., KARADAĞ İ., et al.

Acta Gastro-Enterologica Belgica , cilt.83, sa.3, ss.407-412, 2020 (SCI-Expanded, Scopus)

17. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obes

KARAKAYA S., ALTAY M., Kaplan Efe F., KARADAĞ İ., Ünsal O., Bulur O., et al.

Turkish Journal of Medical Sciences , cilt.49, sa.1, ss.245-248, 2019 (SCI-Expanded, Scopus, TRDizin)

18. The role of insulin - Like growth factor - 1 on steatohepatitis

Dal K., Bulur O., ATA N., Yeniova A. O., Baser S., KARAKAYA S., et al.

Acta Gastro-Enterologica Belgica , cilt.80, sa.1, ss.21-24, 2017 (SCI-Expanded, Scopus)

19. Does Use of Anethum Graveolens Affected Thyroid Hormone Levels and Thyroid Nodules?

ALTAY M., ATEŞ İ., Kaplan Efe F., KARADAĞ İ.

American Journal of Therapeutics , cilt.24, sa.5, 2017 (SCI-Expanded, Scopus)

Doç. Dr. İbrahim KARADAĞ

Yayınlar & Eserler

1. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

2. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

3. Adjuvant Temozolomide Therapy Tolerance in Geriatric Glioblastoma Multiforme Patients

4. Clinicopathological features of non-carcinoid malignant epithelial appendix tumors and risk factors for recurrence, single-center experience

5. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy

6. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

7. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

8. The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer

9. Non-Invasive Liver Fibrosis Scores can Predict Hepatic Metastasis in Colorectal Cancers

10. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer

11. CA-125/CEA RATIO AS A PROGNOSTIC FACTOR IN TYPE II ENDOMETRIAL CANCER: A SINGLE INSTITUTE EXPERIENCE

12. Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study

13. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

14. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data

15. Evaluation of Cancer Patients with Older Adult for Awareness and Hospital Arrival Process of COVID-19 Pandemic During: A Cross-Sectional Study

16. The easy way of evaluating exocrine pancreatic insufficiency in type 2 diabetes: Listen to the patients’ complaints and look in their eyes!

17. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obes

18. The role of insulin - Like growth factor - 1 on steatohepatitis

19. Does Use of Anethum Graveolens Affected Thyroid Hormone Levels and Thyroid Nodules?

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Proje